19335905

Source:http://linkedlifedata.com/resource/pubmed/id/19335905

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0024501, umls-concept:C0036341, umls-concept:C0087111, umls-concept:C0206034, umls-concept:C0871261, umls-concept:C0936012, umls-concept:C1276996, umls-concept:C1704632, umls-concept:C1706817, umls-concept:C2911692
pubmed:dateCreated	2009-4-20
pubmed:abstractText	How long an antipsychotic is effective in maintaining response is important in choosing the correct treatment for people with schizophrenia. This post-hoc analysis describes maintenance of response over 24 or 28 weeks in people treated for schizophrenia with olanzapine, risperidone, quetiapine, ziprasidone, or aripiprazole.
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/19335905-12700715, http://linkedlifedata.com/resource/pubmed/commentcorrection/19335905-12796218, http://linkedlifedata.com/resource/pubmed/commentcorrection/19335905-15000267, http://linkedlifedata.com/resource/pubmed/commentcorrection/19335905-15056516, http://linkedlifedata.com/resource/pubmed/commentcorrection/19335905-15119912, http://linkedlifedata.com/resource/pubmed/commentcorrection/19335905-15741458, http://linkedlifedata.com/resource/pubmed/commentcorrection/19335905-15982856, http://linkedlifedata.com/resource/pubmed/commentcorrection/19335905-16054802, http://linkedlifedata.com/resource/pubmed/commentcorrection/19335905-16172203, http://linkedlifedata.com/resource/pubmed/commentcorrection/19335905-16199834, http://linkedlifedata.com/resource/pubmed/commentcorrection/19335905-16375765, http://linkedlifedata.com/resource/pubmed/commentcorrection/19335905-16585455, http://linkedlifedata.com/resource/pubmed/commentcorrection/19335905-16633144, http://linkedlifedata.com/resource/pubmed/commentcorrection/19335905-16649833, http://linkedlifedata.com/resource/pubmed/commentcorrection/19335905-16974184, http://linkedlifedata.com/resource/pubmed/commentcorrection/19335905-17046983, http://linkedlifedata.com/resource/pubmed/commentcorrection/19335905-17046987, http://linkedlifedata.com/resource/pubmed/commentcorrection/19335905-17287825, http://linkedlifedata.com/resource/pubmed/commentcorrection/19335905-17502771, http://linkedlifedata.com/resource/pubmed/commentcorrection/19335905-17854239, http://linkedlifedata.com/resource/pubmed/commentcorrection/19335905-18794651, http://linkedlifedata.com/resource/pubmed/commentcorrection/19335905-18986646, http://linkedlifedata.com/resource/pubmed/commentcorrection/19335905-3616518, http://linkedlifedata.com/resource/pubmed/commentcorrection/19335905-9315992
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/100968559
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antipsychotic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Benzodiazepines, http://linkedlifedata.com/resource/pubmed/chemical/Dibenzothiazepines, http://linkedlifedata.com/resource/pubmed/chemical/Piperazines, http://linkedlifedata.com/resource/pubmed/chemical/Quinolones, http://linkedlifedata.com/resource/pubmed/chemical/Risperidone, http://linkedlifedata.com/resource/pubmed/chemical/Thiazoles, http://linkedlifedata.com/resource/pubmed/chemical/aripiprazole, http://linkedlifedata.com/resource/pubmed/chemical/olanzapine, http://linkedlifedata.com/resource/pubmed/chemical/quetiapine, http://linkedlifedata.com/resource/pubmed/chemical/ziprasidone
pubmed:status	MEDLINE
pubmed:issn	1471-244X
pubmed:author	pubmed-author:AHH, pubmed-author:Ascher-SvanumHayaH, pubmed-author:BallTamaraT, pubmed-author:ConleyRobertR, pubmed-author:StaufferVirginiaV
pubmed:issnType	Electronic
pubmed:volume	9
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	13
pubmed:dateRevised	2009-11-18
pubmed:meshHeading	pubmed-meshheading:19335905-Adolescent, pubmed-meshheading:19335905-Adult, pubmed-meshheading:19335905-Aged, pubmed-meshheading:19335905-Antipsychotic Agents, pubmed-meshheading:19335905-Benzodiazepines, pubmed-meshheading:19335905-Dibenzothiazepines, pubmed-meshheading:19335905-Female, pubmed-meshheading:19335905-Humans, pubmed-meshheading:19335905-Male, pubmed-meshheading:19335905-Middle Aged, pubmed-meshheading:19335905-Piperazines, pubmed-meshheading:19335905-Quinolones, pubmed-meshheading:19335905-Randomized Controlled Trials as Topic, pubmed-meshheading:19335905-Risperidone, pubmed-meshheading:19335905-Schizophrenia, pubmed-meshheading:19335905-Thiazoles, pubmed-meshheading:19335905-Time Factors, pubmed-meshheading:19335905-Treatment Outcome
pubmed:year	2009
pubmed:articleTitle	Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials.
pubmed:affiliation	Lilly Research Laboratories, Indianapolis, IN, USA. stauffer_virginia@lilly.com
pubmed:publicationType	Journal Article, Comparative Study